Savara (SVRA) Other financing activities (2010 - 2026)
Savara (SVRA) reported Other financing activities of $240000.0 for Q1 2026, up 11.63% year-over-year from $215000.0 in Q1 2025, and down 94.99% quarter-over-quarter from $4.8 million in Q4 2025.
Savara (SVRA) Other financing activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 13 years of Other financing activities data on file, last reported at $240000.0 in Q1 2026.
- Other financing activities for Q1 2026 came in at $240000.0, up 11.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (up 327.57% YoY), and the FY2025 annual result was $5.1 million, up 416.58% from the prior year.
- Other financing activities slipped to $240000.0 in Q1 2026 per SVRA's latest filing, from $4.8 million in the prior quarter.
- Over five years, Other financing activities peaked at $4.8 million in Q4 2025 and troughed at $1000.0 in Q1 2022.
- A 5-year average of $504615.4 and a median of $94000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2025: Other financing activities soared 18100.0% in 2023, then tumbled 75.53% in 2025.
- A 5-year view of Other financing activities shows it stood at $1000.0 in 2022, then soared by 18100.0% to $182000.0 in 2023, then soared by 392.86% to $897000.0 in 2024, then surged by 433.67% to $4.8 million in 2025, then tumbled by 94.99% to $240000.0 in 2026.
- Business Quant data shows SVRA's Other financing activities at $240000.0 in Q1 2026, $4.8 million in Q4 2025, and $23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 240,000.00 |
| Mar 31, 2026 | 240,000.00 |
| Dec 31, 2025 | 4.79 Mn |
| Dec 31, 2025 | 4.79 Mn |
| Sep 30, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 215,000.00 |
| Mar 31, 2025 | 215,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Sep 30, 2024 | 94,000.00 |
| Sep 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Sep 30, 2023 | 182,000.00 |